CAMBRIDGE, MA, USA I November 05, 2018 I Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections, today announced results from preclinical IND-enabling studies of SPR720, an oral antimicrobial agent being developed for the treatment of pulmonary non-tuberculous mycobacterial (NTM) infections. The preclinical in vitro and in vivo toxicology studies demonstrate that SPR720 achieved wide therapeutic margins and activity versus multiple clinically important species of non-tuberculous mycobacteria, which Spero believes supports its advancement into human clinical trials.
“With these encouraging results, we look forward to advancing SPR720 into the clinic in early 2019,” said Ankit Mahadevia, M.D., CEO of Spero Therapeutics. “SPR720 offers the potential to address an important unmet need as the first oral agent for the treatment of pulmonary NTM, a chronic debilitating disease with limited treatment options.”
SPR720 was assessed in a series of non-clinical studies, including IND-enabling 28- and 31-day GLP toxicology studies in non-human primates and rats, respectively, and safety pharmacology studies. In vitro MIC studies demonstrated potent activity for SPR720 against prevalent NTM pathogens, including Mycobacterium avium complex and Mycobacterium abscessus. Furthermore, in vivo studies in murine models of pneumonia demonstrated favorable efficacy relative to standard-of-care comparator agents. The data suggest that SPR720 has an acceptable safety profile, encouraging target pathogen efficacy, and a wide therapeutic margin. These results, in conjunction with the recent regulatory interactions Spero has had, support the further development of SPR720. Spero plans to initiate a First-in-Human Phase 1 clinical trial of SPR720 in early 2019.
SPR720 Research Support
Research reported in this publication was supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under Award Number R44AI131749. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
About SPR720
SPR720 represents a novel class of antibacterial agents that target enzymes essential for bacterial DNA replication. SPR720 was in-licensed from Vertex and is being developed as an oral therapy for the treatment of pulmonary non-tuberculous mycobacterial (NTM) infections. NTM are ubiquitous environmental pathogens that can cause progressive lung damage and respiratory failure, particularly in patients with compromised immune systems or underlying pulmonary disorders. Although rare, the incidence of pulmonary NTM infections is increasing worldwide. Treatment of pulmonary NTM infections requires prolonged therapy (continuing for approximately 12 to 24 months) with a combination regimen and is frequently complicated by tolerability and/or toxicity issues. Additionally, there are currently no oral antibiotics specifically approved for use to treat pulmonary NTM infections. Thus, if successfully developed, SPR720 has the potential to address an important unmet need as the first oral antibiotic approved for the treatment of this debilitating disease. Pre-clinical in vitro and in vivo studies have demonstrated potency for SPR720 against a range of bacteria that cause pulmonary NTM infections, including Mycobacterium avium complex and Mycobacterium abscessus, a highly resistant strain responsible for high mortality. Spero believes that its intellectual property portfolio for SPR720 will provide protection globally, including in the United States and Europe, through 2033.
About Spero Therapeutics
Spero Therapeutics, Inc. is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multidrug-resistant (MDR) bacterial infections.
Spero’s lead product candidate, SPR994, is designed to be the first oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections.
Spero also has a platform technology known as its Potentiator Platform that it believes will enable it to develop drugs that will expand the spectrum and potency of existing antibiotics, including formerly inactive antibiotics, against Gram-negative bacteria. Spero’s lead product candidates generated from its Potentiator Platform are two intravenous, or IV-administered agents, SPR741 and SPR206, designed to treat MDR Gram-negative infections in the hospital setting.
Spero is also advancing SPR720, its novel oral therapy product candidate designed for the treatment of pulmonary non-tuberculous mycobacterial (NTM) infections.
For more information, visit https://sperotherapeutics.com.
SOURCE: Spero Therapeutics
Post Views: 88
CAMBRIDGE, MA, USA I November 05, 2018 I Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections, today announced results from preclinical IND-enabling studies of SPR720, an oral antimicrobial agent being developed for the treatment of pulmonary non-tuberculous mycobacterial (NTM) infections. The preclinical in vitro and in vivo toxicology studies demonstrate that SPR720 achieved wide therapeutic margins and activity versus multiple clinically important species of non-tuberculous mycobacteria, which Spero believes supports its advancement into human clinical trials.
“With these encouraging results, we look forward to advancing SPR720 into the clinic in early 2019,” said Ankit Mahadevia, M.D., CEO of Spero Therapeutics. “SPR720 offers the potential to address an important unmet need as the first oral agent for the treatment of pulmonary NTM, a chronic debilitating disease with limited treatment options.”
SPR720 was assessed in a series of non-clinical studies, including IND-enabling 28- and 31-day GLP toxicology studies in non-human primates and rats, respectively, and safety pharmacology studies. In vitro MIC studies demonstrated potent activity for SPR720 against prevalent NTM pathogens, including Mycobacterium avium complex and Mycobacterium abscessus. Furthermore, in vivo studies in murine models of pneumonia demonstrated favorable efficacy relative to standard-of-care comparator agents. The data suggest that SPR720 has an acceptable safety profile, encouraging target pathogen efficacy, and a wide therapeutic margin. These results, in conjunction with the recent regulatory interactions Spero has had, support the further development of SPR720. Spero plans to initiate a First-in-Human Phase 1 clinical trial of SPR720 in early 2019.
SPR720 Research Support
Research reported in this publication was supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under Award Number R44AI131749. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
About SPR720
SPR720 represents a novel class of antibacterial agents that target enzymes essential for bacterial DNA replication. SPR720 was in-licensed from Vertex and is being developed as an oral therapy for the treatment of pulmonary non-tuberculous mycobacterial (NTM) infections. NTM are ubiquitous environmental pathogens that can cause progressive lung damage and respiratory failure, particularly in patients with compromised immune systems or underlying pulmonary disorders. Although rare, the incidence of pulmonary NTM infections is increasing worldwide. Treatment of pulmonary NTM infections requires prolonged therapy (continuing for approximately 12 to 24 months) with a combination regimen and is frequently complicated by tolerability and/or toxicity issues. Additionally, there are currently no oral antibiotics specifically approved for use to treat pulmonary NTM infections. Thus, if successfully developed, SPR720 has the potential to address an important unmet need as the first oral antibiotic approved for the treatment of this debilitating disease. Pre-clinical in vitro and in vivo studies have demonstrated potency for SPR720 against a range of bacteria that cause pulmonary NTM infections, including Mycobacterium avium complex and Mycobacterium abscessus, a highly resistant strain responsible for high mortality. Spero believes that its intellectual property portfolio for SPR720 will provide protection globally, including in the United States and Europe, through 2033.
About Spero Therapeutics
Spero Therapeutics, Inc. is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multidrug-resistant (MDR) bacterial infections.
Spero’s lead product candidate, SPR994, is designed to be the first oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections.
Spero also has a platform technology known as its Potentiator Platform that it believes will enable it to develop drugs that will expand the spectrum and potency of existing antibiotics, including formerly inactive antibiotics, against Gram-negative bacteria. Spero’s lead product candidates generated from its Potentiator Platform are two intravenous, or IV-administered agents, SPR741 and SPR206, designed to treat MDR Gram-negative infections in the hospital setting.
Spero is also advancing SPR720, its novel oral therapy product candidate designed for the treatment of pulmonary non-tuberculous mycobacterial (NTM) infections.
For more information, visit https://sperotherapeutics.com.
SOURCE: Spero Therapeutics
Post Views: 88
